EXTI - only public co. developing liver device Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : EXTI - only public co. developing liver device

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Danny Kim who started this subject	4/21/2004 5:10:38 PM
From: MaxLeverage	of 1063

216.239.53.104 Pharmacokinetic Studies: the Earlier the Better PK properties can make or break a new drug, forcing companies to conduct ADME studies sooner in the discovery process JR Minkel Minkel is a freelance writer based in based in Brooklyn, N.Y. Early drug metabolism models help predict a compound's elimination from the body, or metabolic stability, which affects its duration of action. At Xenotech LLC, Lenexa, Kan., researchers incubate the compound and whole human hepatocytes manually in test tubes for 1 hour. They use low substrate concentrations at first to mimic the likely levels of drug in the human body. High-performance liquid chromatography or liquid chromatography-mass spectrometry (LCMS) tells them the concentration of compound at successive intervals. They compare results to compounds with known stabilities and can establish a half-life for the test compound.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next